Valuation : BICO Group AB

Market Cap 1.56B 163M 140M 132M 120M 225M 15.46B 226M 605M 7.9B 612M 599M 25.15B P/E 2026 *
-6.88x
P/E 2027 * -12.4x
Enterprise Value 1.49B 156M 134M 126M 115M 215M 14.78B 216M 578M 7.55B 585M 573M 24.04B EV / Sales 2026 *
0.92x
EV / Sales 2027 * 0.83x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
1 day+35.29%
1 month+35.29%
3 months+8.83%
6 months+1.97%
Current year-15.85%
1 month 2.07
Extreme 2.07
2.07
Current year 1.52
Extreme 1.522
2.31
1 year 1.52
Extreme 1.522
2.73
3 years 1.52
Extreme 1.522
6.9
5 years 1.52
Extreme 1.522
64.5
10 years 0
Extreme 0
100
Manager TitleAgeSince
Chief Executive Officer 51 01/09/2026
Director of Finance/CFO 56 01/03/2026
Chief Operating Officer - 07/01/2026
Director TitleAgeSince
Director/Board Member 70 18/12/2019
Director/Board Member 37 01/03/2015
Director/Board Member - 07/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
+35.29%-.--% - - 163M
+0.55%+0.86%+24.21%+16.87% 227B
-1.20%-0.50%+3.66%-17.10% 146B
-3.87%-4.75%-25.16%+17.94% 130B
-4.61%-5.95%-58.18%-16.06% 69.27B
-3.57%-3.95%+8.66%+17.67% 51.82B
+0.98%-0.33%-17.44%-14.25% 49.99B
-3.10%-1.94%+14.74%+28.98% 42.53B
-1.41%-0.29%+30.80%+53.53% 40.22B
-3.28%+1.94%+115.06%+33.33% 32.95B
Average +1.65%-0.93%+10.71%+13.44% 87.69B
Weighted average by Cap. -1.56%-1.41%+5.03%+9.16%

Financials

2026 *2027 *
Net sales 1.62B 169M 146M 137M 125M 233M 16.04B 234M 628M 8.2B 636M 622M 26.1B 1.69B 176M 151M 142M 130M 242M 16.67B 244M 652M 8.52B 660M 646M 27.12B
Net income -227M -23.69M -20.36M -19.16M -17.48M -32.63M -2.25B -32.8M -87.82M -1.15B -88.94M -87M -3.65B -126M -13.15M -11.3M -10.63M -9.7M -18.11M -1.25B -18.2M -48.75M -637M -49.37M -48.29M -2.03B
Net Debt -69M -7.2M -6.19M -5.82M -5.31M -9.92M -683M -9.97M -26.7M -349M -27.03M -26.44M -1.11B -166M -17.32M -14.89M -14.01M -12.79M -23.86M -1.64B -23.98M -64.22M -839M -65.04M -63.62M -2.67B
Logo BICO Group AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
554
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
21.15SEK
Average target price
29.00SEK
Spread / Average Target
+37.12%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!